AISA Pharma Achieves Orphan Drug Designation for SSc
AISA Pharma, Inc., a private biopharmaceutical company in the clinical stage, has made a significant announcement. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AISA-021 (cilnidipine), a new fourth-generation calcium channel antagonist. This milestone is a crucial advancement in the company's efforts to tackle systemic sclerosis (SSc), a rare autoimmune disease that affects around 175,000 people in the United States.
What is Systemic Sclerosis?
Systemic Sclerosis, commonly referred to as scleroderma, is recognized as one of the most lethal autoimmune diseases, with a concerning mortality rate that underscores the urgent need for effective treatment options. It primarily impacts the skin and internal organs, leading to severe complications. The orphan drug designation for AISA-021 indicates its potential to assist patients by not only reducing disease severity but also enhancing their quality of life.
Breakthrough in Treatment Options
Dr. Andrew Sternlicht, the CEO and Founder of AISA Pharma, expressed his thoughts on this pivotal moment. "To our knowledge, this is the first instance where the FDA has granted orphan drug designation to a calcium channel antagonist for an autoimmune condition. We are hopeful that this designation will expedite our development program for AISA-021, with the goal of creating an effective and well-tolerated treatment for patients suffering from SSc," stated Dr. Sternlicht.
The Importance of Orphan Drug Designation
The FDA's Orphan Drug Act offers various incentives for developing treatments for rare diseases, such as tax credits, grants, and a seven-year market exclusivity following drug approval. This supportive environment fosters innovative solutions to complex health challenges, providing companies like AISA Pharma with a significant advantage during the research and development process.
Updates on Clinical Studies
AISA Pharma has been actively engaged in a Phase 2 study that has yielded promising results. The ongoing clinical trial, which includes 60 participants, has demonstrated improved outcomes across several key endpoints compared to a placebo. Notable improvements were observed in overall disease severity, gastrointestinal issues, skin ulcers, and even symptoms related to Raynaud's phenomenon, which is commonly experienced by SSc patients.
Future Research Developments
The company has a Pre-IND meeting scheduled with the FDA to discuss AISA-021's application for treating Systemic Sclerosis and Secondary Raynaud's phenomenon. This meeting represents a vital step in ensuring compliance with FDA requirements and advancing the drug's development process.
Moreover, initial drug screenings conducted by the NIH through the Preclinical Pain Screening Platform have indicated that AISA-021 poses no abuse liability or addictive potential, highlighting its safety as a therapeutic option.
Participation in Major Scientific Conferences
AISA Pharma is preparing to present two significant abstracts at the upcoming ACR Convergence Scientific Meeting. These presentations will offer further insights into the efficacy and safety profile of AISA-021 in addressing Raynaud's symptoms and broader SSc concerns.
About AISA-021
AISA-021 is based on cilnidipine, a fourth-generation calcium channel blocker known for its selectivity towards N-type calcium channels. While it has been commonly used in certain Asian countries for hypertension, it has yet to receive approval in the U.S., Europe, or Canada. This new designation represents a potential turning point in the treatment options available for patients with SSc, particularly given the limited effectiveness of current therapies.
Understanding Systemic Sclerosis
Systemic Sclerosis has a profound impact on patient health, with an astonishing 95% of those affected experiencing Raynaud's symptoms, which can cause significant discomfort. This emphasizes the importance of AISA Pharma's ongoing efforts. Currently, no drug has been approved globally for treating Raynaud's symptoms, highlighting the opportunity for AISA-021 to address a critical gap in available treatments.
About AISA Pharma Inc.
Founded in 2019, AISA Pharma Inc. is committed to advancing innovative biopharmaceutical treatments. Based in Boston, MA, the company strives to improve patient care through targeted therapies aimed at challenging medical conditions. For more details about the company and its groundbreaking research, please visit their website.
Frequently Asked Questions
What does the FDA's orphan drug designation mean?
The orphan drug designation offers incentives to companies developing treatments for rare diseases, such as tax benefits and market exclusivity, which helps promote research and development efforts.
How is AISA-021 intended to treat systemic sclerosis?
AISA-021 is designed to alleviate symptoms of systemic sclerosis by improving blood flow and potentially easing pain associated with the condition.
What are Raynaud's symptoms and why are they important?
Raynaud's symptoms involve reduced blood flow to extremities, resulting in severe pain and discomfort. They affect 95% of systemic sclerosis patients and are often cited as their most debilitating symptom.
When will AISA Pharma present at the ACR meeting?
AISA Pharma is scheduled to present at the ACR Convergence Scientific Meeting, showcasing findings from their ongoing studies involving AISA-021.
Where can I learn more about AISA Pharma?
For additional information about AISA Pharma, including their research initiatives, please visit the company's website.
